Sanofi (SNY) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.98
- Estimate
- $1.51
- Surprise
- +31.2%
- Score today
- 6.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Sanofi (SNY) beat the $1.51 estimate with adjusted EPS of $1.98 — a large 31.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SNY Buy (Wait) at 6.0/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +31.2% surprise compares with a +12.9% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Thin upside margin: 5.2%
- Weak growth
- News modifier +2: HOLD_IF_HOLDING → STRONG_BUY_WAIT
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $44.34
- Entry target
- $43.67
- Price target
- $46.64
- Stop
- $41.71
- Upside to target
- +5.2%
- Reward-to-risk
- 0.4:1
The stock trades at 22.1× trailing but 8.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 3.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-31 — shown for context, not personalized investment advice.
SNY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $106.24B
- P/E (fwd)
- 8.5
- P/E (ttm)
- 22.1
- 52-week range
- $39.07–$52.68
- Off 52-week high
- 15.8%
- RSI (14)
- 74
- Volume vs avg
- 3.78×
- Score today
- 6.0/10